AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City
ByAinvest
Thursday, Aug 21, 2025 9:33 pm ET1min read
RenovoRx CEO Shaun Bagai will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. The presentation will cover the company's commercialization efforts and Phase III TIGeR-PaC clinical trial developments for its oncology therapies. Bagai will also discuss RenovoRx's patented RenovoCath drug-delivery device and its organic revenue growth. The presentation will be available on the company's investor relations website.
RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, has announced that its CEO, Shaun Bagai, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [1]. The presentation will cover the company's ongoing commercialization efforts, organic revenue growth, and the latest developments in its Phase III TIGeR-PaC clinical trial.Mr. Bagai will discuss RenovoRx’s ongoing commercialization efforts, highlighting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. He will also present updates on the company's Phase III TIGeR-PaC trial, which is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC) [2].
The TIGeR-PaC trial is currently under investigation and has not been approved for commercial sale. However, it has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon new drug application approval by the FDA [3].
RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. The company has already received its first commercial purchase orders for RenovoCath devices and has initiated repeat orders from several high-volume National Cancer Institute-designated centers [4].
Mr. Bagai’s presentation will be available for the duration of the conference and afterwards on the Company's IR website. To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@KCSA.com.
References:
[1] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
[2] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
[3] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
[4] https://www.nasdaq.com/press-release/renovorx-ceo-shaun-bagai-present-hc-wainwrights-27th-annual-global-investment
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet